Grufity logoGrufity logo

BSX

46.60USD+0.48(+1.04%)Market Closed

Boston Scientific Corp

Market Summary

USD46.60+0.48Market Closed
1.04%

BSX Alerts

BSX Stock Price

RSI Chart

Valuation

Market Cap

61.8B

Price/Earnings

69.9

Price/Sales

5.01

Price/Cashflow

51.84

MarketCap/EBT

56.02

Price/Sales

Profitability

EBT Margin

8.95%

Return on Equity

5.12%

Return on Assets

2.75%

Fundamentals

Revenue

Revenue (TTM)

12.3B

Revenue Y/Y

5.43%

Revenue Q/Q

7.2%

Earnings

Earnings (TTM)

884.0M

Earnings Y/Y

39.78%

Earnings Q/Q

136.36%

Price Action

52 Week Range

34.9847.50
(Low)(High)

Last 7 days

5.6%

Last 30 days

11.1%

Last 90 days

15.1%

Trailing 12 Months

17.7%

Financial Health

Current Ratio

1.31

Debt/Equity

0.51

Debt/Cashflow

0.14

Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

0.58

Peers (Alternatives to Boston Scientific)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-11.88% 44.84%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
14.69% -0.88%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
15.30% -16.82%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.69% 8.01%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
11.14% 17.68%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
8.87% -30.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
15.24% 17.79%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.98% -14.84%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-8.48% 5.83%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-16.73% -66.49%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
26.44% 24.39%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
9.49% -7.06%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.05% -10.97%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-6.64% -29.40%
-16.43
2.57
-8.79% -175.19%

Financials for Boston Scientific

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue1.4%12,32912,16211,88811,47011,197
Gross Profit1.2%8,4918,3908,1777,7307,488
Operating Expenses-0.8%7,0357,0956,9786,6617,011
  S&GA Expenses1.0%4,4444,4004,3594,2334,151
Earnings Before Taxes21.6%1,1039071,0761,264554
Net Income9.1%8848101,0411,156582
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-0.5%32,18932,33732,22931,87731,168
  Current Assets0.4%5,0835,0656,3176,2296,758
    Cash Equivalents-15.1%2763251,9251,9472,675
  Inventory0.9%1,7521,7361,6101,6031,430
  Net PPE-0.8%2,2462,2652,2522,1092,082
  Goodwill-0.5%12,88312,94911,98811,82010,874
  Current Liabilities-9.2%3,8834,2754,2744,0224,073
  Long Term Debt-2.9%8,8029,0678,8048,8248,847
Shareholder's Equity3.1%17,25116,73516,62216,46215,942
  Retained Earnings19.0%-1,050.00-1,296.00-1,392.00-1,473.00-1,878.00
  Additional Paid-In Capital0.3%20,10320,04319,98619,93019,817
Shares Outstanding0.1%1,4301,4281,4241,421-
Float-60,600----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-22.0%1,1921,5281,8702,0652,243
  Share Based Compensation4.0%207199194187176
Cashflow From Investing-0.9%-3,271.00-3,242.00-1,597.00-1,283.00-205.00
Cashflow From Financing-5766.7%-352.00-6.00-95.00-906.00-1,161.00
  Dividend Payments0%5555555656
  Buy Backs-0
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on BSX?

29.2%


Probability that Boston Scientific stock will be more than 20% underwater in next one year

18.5%


Probability that Boston Scientific stock will be more than 30% underwater in next one year.

16.1%


Probability that Boston Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BSX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Boston Scientific was unfortunately bought at previous high price.

Returns

Cumulative Returns on BSX

23.7%


10-Year Cumulative Returns

14.1%


7-Year Cumulative Returns

12.3%


5-Year Cumulative Returns

3.0%


3-Year Cumulative Returns

What are the long-term rolling returns for BSX?

FIve years rolling returns for Boston Scientific.

Which funds bought or sold BSX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-84.25
-11,492
2,000
-%
2022-11-23
Toroso Investments, LLC
ADDED
5.96
207,000
2,256,000
0.09%
2022-11-23
Gould Capital, LLC
REDUCED
-0.67
29,000
936,000
0.81%
2022-11-22
CVA Family Office, LLC
ADDED
952.63
35,000
39,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
18,856,000
18,856,000
0.22%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
8.7
47,000
407,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.94
2,665,000
93,251,000
0.16%
2022-11-21
Topel & Distasi Wealth Management, LLC
UNCHANGED
-
35,000
296,000
0.16%
2022-11-21
FourThought Financial, LLC
ADDED
40.62
44,000
140,000
0.02%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
1,062,000
1,062,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying BSX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BSX

Boston Scientific News

Investing.com

7 biggest deal reports this week: Horizon Therapeutics surges on takeover talks By Investing.com.113 minutes ago

BSX Fair Value

Recent SEC filings of Boston Scientific

View All Filings
Date Filed Form Type Document
Nov 30, 2022
4
Insider Trading
Nov 21, 2022
4
Insider Trading
Nov 21, 2022
8-K
Current Report
Nov 15, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Oct 26, 2022
8-K
Current Report
Oct 18, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for BSX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-29
Connors Nelda J
SOLD
-809,243
44.4737
-18,196
-
2022-11-18
Thepaut Eric Francis Yves
SOLD
-638,773
42.7216
-14,952
EVP & Pres, Eur, Mid-East, Afr
2022-11-15
Carruthers Wendy
SOLD
-71,482.8
42.6
-1,678
EVP, Human Resources
2022-11-07
Mahoney Michael F
SOLD
-5,281,000
41.9703
-125,827
Chairman, President & CEO
2022-11-07
Mahoney Michael F
ACQUIRED
1,176,010
9.34625
125,827
Chairman, President & CEO
2022-10-17
Carruthers Wendy
SOLD
-539,744
40.5152
-13,322
EVP, Human Resources
2022-09-15
Carruthers Wendy
SOLD
-316,586
42.2114
-7,500
EVP, Human Resources
2022-09-06
Mahoney Michael F
SOLD
-5,094,310
40.4863
-125,828
Chairman, President & CEO
2022-09-06
Mahoney Michael F
ACQUIRED
1,176,020
9.34628
125,828
Chairman, President & CEO
2022-08-30
Mahoney Michael F
GIFTED
-
-
-365,457
Chairman, President & CEO

1–10 of 50

Michael F. Mahoney
41000
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

BSX Income Statement

2022-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net sales$ 3,170$ 2,932$ 9,440$ 8,761
Cost of products sold9799002,9452,739
Gross profit2,1912,0326,4956,022
Operating expenses:    
Selling, general and administrative expenses1,1321,0663,3573,206
Research and development expenses339310993884
Royalty expense11143438
Amortization expense202184604549
Intangible asset impairment charges125128132173
Contingent consideration net expense (benefit)20(26)68(117)
Restructuring net charges (credits)491818
Litigation-related net charges (credits)0042302
Gain on disposal of businesses and assets0(40)0(48)
Operating expenses1,8331,6455,2485,003
Operating income (loss)3583871,2471,019
Other income (expense):    
Interest expense(63)(86)(406)(254)
Other, net(51)181(96)192
Income (loss) before income taxes245483745957
Income tax expense (benefit)576418810
Net income (loss)188419558946
Preferred stock dividends(14)(14)(42)(42)
Net income (loss) available to common stockholders$ 174$ 405$ 516$ 905
Net income (loss) per common share — basic$ 0.12$ 0.28$ 0.36$ 0.64
Net income (loss) per common share — assuming dilution$ 0.12$ 0.28$ 0.36$ 0.63
Weighted-average shares outstanding    
Basic1,431.61,423.81,429.71,421.3
Assuming dilution1,440.01,435.61,438.71,433.0

BSX Balance Sheet

2022-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 338$ 1,925
Trade accounts receivable, net1,8711,778
Inventories1,7881,610
Prepaid income taxes262205
Other current assets884799
Total current assets5,1446,317
Property, plant and equipment, net2,2732,252
Goodwill12,85211,988
Other intangible assets, net6,0586,121
Deferred tax assets4,0184,142
Other long-term assets1,6021,410
TOTAL ASSETS31,94732,229
Current liabilities:  
Current debt obligations20261
Accounts payable803794
Accrued expenses1,9742,436
Other current liabilities752783
Total current liabilities3,5494,274
Long-term debt8,5648,804
Deferred income taxes278310
Other long-term liabilities1,9162,220
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of September 30, 2022 and December 31, 202100
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,695,397,636 shares as of September 30, 2022 and 1,688,810,052 shares as of December 31, 20211717
Treasury stock, at cost - 263,289,848 shares as of September 30, 2022 and December 31, 2021(2,251)(2,251)
Additional paid-in capital20,21919,986
Accumulated deficit(876)(1,392)
Accumulated other comprehensive income (loss), net of tax532263
Total stockholders’ equity17,64016,622
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 31,947$ 32,229